{
    "data": [
        {
            "id": "4474873",
            "type": "article",
            "attributes": {
                "publishOn": "2021-12-13T08:30:00-05:00",
                "isLockedPro": false,
                "commentCount": 12,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1215141883/image_1215141883.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Organon Is Too Cheap To Ignore And Set To Soar",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105703",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "352827",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "610617",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4474873-organon-too-cheap-to-ignore-set-to-soar"
            }
        },
        {
            "id": "4474886",
            "type": "article",
            "attributes": {
                "publishOn": "2021-12-13T07:28:18-05:00",
                "isLockedPro": false,
                "commentCount": 15,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1339561324/image_1339561324.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Why Buy Organon After Shares Fell Below $30",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "22786",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "352808",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "610617",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4474886-why-buy-organon-after-shares-fell-below-30"
            }
        },
        {
            "id": "4469086",
            "type": "article",
            "attributes": {
                "publishOn": "2021-11-12T19:38:44-05:00",
                "isLockedPro": false,
                "commentCount": 30,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/96836539/image_96836539.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Organon: Post Earnings Dip Is A Buy Opportunity Based On Jaw-Dropping Fundamentals",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104985",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "349003",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "610617",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4469086-organon-post-earnings-dip-is-a-buy-opportunity-based-on-jaw-dropping-fundamentals"
            }
        },
        {
            "id": "4457077",
            "type": "article",
            "attributes": {
                "publishOn": "2021-09-25T08:36:05-04:00",
                "isLockedPro": false,
                "commentCount": 52,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1251485261/image_1251485261.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Organon Is Merck's Spin-Off And Your New Dividend Prospect",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "80836",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "342789",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "610617",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4457077-organon-is-mercks-spin-off-and-your-new-dividend-prospect"
            }
        },
        {
            "id": "4453789",
            "type": "article",
            "attributes": {
                "publishOn": "2021-09-06T22:33:57-04:00",
                "isLockedPro": false,
                "commentCount": 39,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1194880458/image_1194880458.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Organon Is An Irresistible Bargain, Here's Why",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105703",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "340461",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "610617",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4453789-organon-is-an-irresistible-bargain-heres-why"
            }
        },
        {
            "id": "4449446",
            "type": "article",
            "attributes": {
                "publishOn": "2021-08-14T02:37:41-04:00",
                "isLockedPro": false,
                "commentCount": 18,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1281764188/image_1281764188.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Organon: Q2 Earnings Should Alleviate Bear Concerns",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105585",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "337396",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "610617",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4449446-organon-q2-earnings-should-alleviate-bear-concerns"
            }
        },
        {
            "id": "4440404",
            "type": "article",
            "attributes": {
                "publishOn": "2021-07-21T13:41:30-04:00",
                "isLockedPro": false,
                "commentCount": 16,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1039299984/image_1039299984.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Organon: Merck Spin-Off's Shares Hard To Resist At Current Price",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104985",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "333995",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "610617",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4440404-organon-merck-spin-offs-shares-hard-to-resist-at-current-price"
            }
        },
        {
            "id": "4439869",
            "type": "article",
            "attributes": {
                "publishOn": "2021-07-19T10:02:32-04:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1297651436/image_1297651436.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Organon: Merck's Spinoff Has Potential But More Concrete Actions Awaited",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105503",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "333635",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "610617",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4439869-organon-mercks-spinoff-has-potential"
            }
        },
        {
            "id": "4433176",
            "type": "article",
            "attributes": {
                "publishOn": "2021-06-07T08:30:00-04:00",
                "isLockedPro": false,
                "commentCount": 220,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1220522816/image_1220522816.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Organon: 100% Upside Potential From Recent Pharma Spin-Off",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105585",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "328139",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "610617",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        },
                        {
                            "id": "49641",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/4433176-organon-100-percent-upside-potential-recent-pharma-spin-off"
            }
        }
    ]
}